Feasibility and clinical impact of out-of-ICU noninvasive respiratory support in patients with COVID-19-related pneumonia.


Journal

The European respiratory journal
ISSN: 1399-3003
Titre abrégé: Eur Respir J
Pays: England
ID NLM: 8803460

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 03 06 2020
accepted: 27 07 2020
pubmed: 5 8 2020
medline: 27 11 2020
entrez: 5 8 2020
Statut: epublish

Résumé

The severe acute respiratory syndrome-coronavirus 2 outbreak spread rapidly in Italy and the lack of intensive care unit (ICU) beds soon became evident, forcing the application of noninvasive respiratory support (NRS) outside the ICU, raising concerns over staff contamination. We aimed to analyse the safety of the hospital staff and the feasibility and outcomes of NRS applied to patients outside the ICU. In this observational study, data from 670 consecutive patients with confirmed coronavirus disease 2019 referred to pulmonology units in nine hospitals between March 1 and May 10, 2020 were analysed. Data collected included medication, mode and usage of NRS ( 42 (11.1%) healthcare workers tested positive for infection, but only three of them required hospitalisation. Data are reported for all patients (69.3% male), whose mean±sd age was 68±13 years. The arterial oxygen tension/inspiratory oxygen fraction ratio at baseline was 152±79, and the majority (49.3%) of patients were treated with CPAP. The overall unadjusted 30-day mortality rate was 26.9%, with 16%, 30% and 30% for HFNC, CPAP and NIV, respectively, while the total ETI rate was 27%, with 29%, 25% and 28%, respectively; the relative probability of death was not related to the NRS used after adjustment for confounders. ETI and length of stay were not different among the groups. Mortality rate increased with age and comorbidity class progression. The application of NRS outside the ICU is feasible and associated with favourable outcomes. Nonetheless, it was associated with a risk of staff contamination.

Identifiants

pubmed: 32747398
pii: 13993003.02130-2020
doi: 10.1183/13993003.02130-2020
pmc: PMC7397952
pii:
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright ©ERS 2020.

Déclaration de conflit d'intérêts

Conflict of interest: C. Franco has nothing to disclose. Conflict of interest: N. Faccialongo has nothing to disclose. Conflict of interest: R. Tonelli has nothing to disclose. Conflict of interest: R. Dongilli has nothing to disclose. Conflict of interest: A. Vianello has nothing to disclose. Conflict of interest: L. Pisani has nothing to disclose. Conflict of interest: R. Scala has nothing to disclose. Conflict of interest: M. Malerba has nothing to disclose. Conflict of interest: A. Carlucci has nothing to disclose. Conflict of interest: E.A. Negri has nothing to disclose. Conflict of interest: G. Spoladore has nothing to disclose. Conflict of interest: G. Arcaro has nothing to disclose. Conflict of interest: P.A. Tillio has nothing to disclose. Conflict of interest: C. Lastoria has nothing to disclose. Conflict of interest: G. Schifino has nothing to disclose. Conflict of interest: L. Tabbì has nothing to disclose. Conflict of interest: L. Guidelli has nothing to disclose. Conflict of interest: G. Guaraldi has nothing to disclose. Conflict of interest: V.M. Ranieri has nothing to disclose. Conflict of interest: E. Clini has nothing to disclose. Conflict of interest: S. Nava has nothing to disclose.

Références

JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
JAMA. 2020 Apr 28;323(16):1612-1614
pubmed: 32191259
Eur Respir J. 2020 Jun 4;55(6):
pubmed: 32366488
J Crit Care. 2018 Dec;48:178-182
pubmed: 30216936
Eur Respir Rev. 2020 Apr 3;29(155):
pubmed: 32248146
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
Eur Respir J. 2020 Aug 13;56(2):
pubmed: 32430410
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
N Engl J Med. 2020 Jun 4;382(23):2267-2268
pubmed: 32294342
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Eur Respir J. 2017 Aug 31;50(2):
pubmed: 28860265
N Engl J Med. 2020 May 21;382(21):2012-2022
pubmed: 32227758
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1430-1434
pubmed: 32267160
Lancet. 2020 Apr 11;395(10231):1225-1228
pubmed: 32178769
Intensive Care Med. 2020 May;46(5):854-887
pubmed: 32222812

Auteurs

Cosimo Franco (C)

Respiratory Intensive Care Unit - AUSL, Piacenza, Italy.
Contributed equally to the work and should both be considered as first author.

Nicola Facciolongo (N)

Respiratory Unit AUSL Reggio Emilia, IRCCS di Reggio Emilia, Modena, Italy.
Contributed equally to the work and should both be considered as first author.

Roberto Tonelli (R)

Clinical and Experimental Medicine PhD Programme, University of Modena Reggio Emilia, Modena, Italy.
University Hospital of Modena, Respiratory Diseases Unit, Dept of Medical and Surgical Sciences SMECHIMAI, University of Modena Reggio Emilia, Modena, Italy.

Roberto Dongilli (R)

Division of Respiratory Diseases with Intermediate Respiratory Intensive Care Units, Central Hospital of Bolzano, Bolzano, Italy.

Andrea Vianello (A)

Respiratory Pathophysiology Division University of Padova, Padova, Italy.

Lara Pisani (L)

Respiratory and Critical Care Unit, Sant'Orsola Hospital, Bologna Dept of Specialist, Diagnostic, and Experimental Medicine, School of Medicine, University di Bologna, Bologna, Italy.

Raffaele Scala (R)

Pulmonology and Respiratory Intensive Care Unit, S. Donato Hospital, Arezzo, Italy.

Mario Malerba (M)

Dept of Translational Medicine, Università Piemonte Orientale, Respiratory Unit, Ospedale S. Andrea, Vercelli, Italy.

Annalisa Carlucci (A)

Dipartimento di Medicina e Chirurgia, Università Insubria Varese-Como, ICS Maugeri, Pavia, Italy.

Emanuele Alberto Negri (EA)

Respiratory Unit AUSL Reggio Emilia, IRCCS di Reggio Emilia, Modena, Italy.

Greta Spoladore (G)

Division of Infectious Diseases, Central Hospital of Bolzano, Bolzano, Italy.

Giovanna Arcaro (G)

Respiratory Pathophysiology Division University of Padova, Padova, Italy.

Paolo Amedeo Tillio (PA)

Dept of Translational Medicine, Università Piemonte Orientale, Respiratory Unit, Ospedale S. Andrea, Vercelli, Italy.

Cinzia Lastoria (C)

Respiratory Rehabilitation Unit, ICS Maugeri, Pavia, Italy.

Gioachino Schifino (G)

Respiratory and Critical Care Unit, Sant'Orsola Hospital, Bologna Dept of Specialist, Diagnostic, and Experimental Medicine, School of Medicine, University di Bologna, Bologna, Italy.

Luca Tabbì (L)

University Hospital of Modena, Respiratory Diseases Unit, Dept of Medical and Surgical Sciences SMECHIMAI, University of Modena Reggio Emilia, Modena, Italy.

Luca Guidelli (L)

Pulmonology and Respiratory Intensive Care Unit, S. Donato Hospital, Arezzo, Italy.

Giovanni Guaraldi (G)

Infectious Diseases Unit, University Hospital of Modena Policlinico. University of Modena Reggio Emilia, Modena, Italy.

V Marco Ranieri (VM)

Alma Mater Studiorum - Università di Bologna, Dipartimento di Scienze Mediche e Chirurgiche, Anesthesia and Intensive Care Medicine, Policlinico di Sant'Orsola, Bologna, Italy.

Enrico Clini (E)

University Hospital of Modena, Respiratory Diseases Unit, Dept of Medical and Surgical Sciences SMECHIMAI, University of Modena Reggio Emilia, Modena, Italy.
Contributed equally to the work and should both be considered as senior author.

Stefano Nava (S)

Alma Mater Studiorum - Università di Bologna, Dipartimento di Scienze Mediche e Chirurgiche, Infectious Diseases Unit, Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
Contributed equally to the work and should both be considered as senior author.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH